目的 探討孟魯司特鈉聯(lián)合喜炎平注射液治療小兒呼吸道合胞病毒感染肺炎的療效觀察。方法 選取2018年1月—2019年12月阜南縣人民醫(yī)院收治的90例小兒呼吸道合胞病毒感染肺炎患兒，按照治療方法將患兒分為對照組和觀察組，每組各45例。對照組喜炎平注射液與100 mL 5%葡萄糖溶液混合靜脈滴注，5 mg/（kg·d），1次/d，療程為2周。觀察組在對照組治療的基礎(chǔ)上口服孟魯司特鈉片，10 mg/次，1次/d，持續(xù)治療2周。對比兩組患者臨床治療效果、臨床癥狀改善時間、可溶性細胞間黏附分子1（sICAM-1）、半胱氨酰白三烯（CysLTs）水平及再次喘息發(fā)生率。結(jié)果 治療后，觀察組臨床總有效率為95.56%，顯著高于對照組的80.00%，差異具有統(tǒng)計學差異（P<0.05）。治療后，觀察組患者喘息改善時間，退燒時間和啰音消失時間均短于對照組，差異具有統(tǒng)計學差異（P<0.05）。治療后，兩組外周血sICAM-1、CysLTs水平均低于治療前，且觀察組外周血sICAM-1、CysLTs水平顯著低于對照組，差異具有統(tǒng)計學差異（P<0.05）。治療期間，觀察組再次喘息發(fā)生率低于對照組，差異具有統(tǒng)計學差異（P<0.05）。結(jié)論 孟魯司特鈉聯(lián)合喜炎平注射液治療小兒呼吸道合胞病毒感染肺炎有較好的療效，有助于降低sICAM-1和CysLTs水平，臨床上值得繼續(xù)推廣。

Objective To observe the curative effect of montelukast sodium combined with Xiyanping Injection in treatment of children with respiratory syncytial virus pneumonia. Methods A total of 90 children with respiratory syncytial virus (RSV) infection pneumonia admitted to Funan County People's Hospital from January 2018 to December 2019 were selected and divided into control group and observation group according to treatment methods, with 45 cases in each group. Patients in the control group were iv administered with Xiyanping Injection, 5 mg/(kg·d), and 100 mL 5% glucose solution were mixed intravenously, once daily for 2 weeks. Patients in the observation group were po administered with Montelukast Sodium Tablets on the basis of control group, 10 mg/time, once daily for 2 weeks. The clinical treatment effect, clinical symptom improvement time, the levels of SICAM-1, CYSLTs and the incidence of re-wheezing were compared between two groups. Results After treatment, the total clinical effective rate of the observation group was 95.56%, significantly higher than that of the control group (80.00%), and the difference was statistically significant (P < 0.05). After treatment, the improved wheezing time, fever reduction time, and rale disappearance time in the observation group were shorter than those in the control group, with statistical differences (P < 0.05). After treatment, the levels of sICAM-1, CysLTs in peripheral blood of two groups were lower than before treatment, and the levels of sICAM-1 and CysLTs in peripheral blood of the observation group were significantly lower than the control group, the difference was statistically significant (P < 0.05). During treatment, the incidence of second wheezing in the observation group was lower than that in the control group, with statistical difference (P < 0.05). Conclusion Montelukast sodium combined with Xiyanping Injection has a good efficacy in treatment of respiratory syncytial virus pneumonia in children, which helps to reduce the levels of SICAM-1 and CYSLTs, and is worthy of further promotion in clinical practice.

安徽省衛(wèi)生健康委員會科研計劃項目（2019SEY008）